These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 9258744)
1. Exploiting and bypassing the bone remodeling cycle to optimize the treatment of osteoporosis. Dempster DW J Bone Miner Res; 1997 Aug; 12(8):1152-4. PubMed ID: 9258744 [No Abstract] [Full Text] [Related]
2. Effects of parathyroid hormone and alendronate alone or in combination in osteoporosis. Miller PD N Engl J Med; 2004 Jan; 350(2):189-92; author reply 189-92. PubMed ID: 14714279 [No Abstract] [Full Text] [Related]
3. Combination and sequential therapy for osteoporosis. Heaney RP; Recker RR N Engl J Med; 2005 Aug; 353(6):624-5. PubMed ID: 16093472 [No Abstract] [Full Text] [Related]
4. [Parathyroid and bone. Evidence and perspective of parathyroid therapy for patients with osteoporosis]. Wada S; Fukawa T; Kamiya S Clin Calcium; 2007 Dec; 17(12):1888-94. PubMed ID: 18057665 [TBL] [Abstract][Full Text] [Related]
5. Effects of parathyroid hormone and alendronate alone or in combination in osteoporosis. Sugiyama T; Tanaka H; Kawai S N Engl J Med; 2004 Jan; 350(2):189-92; author reply 189-92. PubMed ID: 14714280 [No Abstract] [Full Text] [Related]
6. Decimal point--osteoporosis therapy at the 10-year mark. Strewler GJ N Engl J Med; 2004 Mar; 350(12):1172-4. PubMed ID: 15028820 [No Abstract] [Full Text] [Related]
7. Mechanisms of bone loss and gain in untreated and treated osteoporosis. Compston J Endocrine; 2002 Feb; 17(1):21-7. PubMed ID: 12014699 [No Abstract] [Full Text] [Related]
8. Alendronate: a bisphosphonate for treatment of osteoporosis. Kirk JK; Spangler JG Am Fam Physician; 1996 Nov; 54(6):2053-60. PubMed ID: 8900364 [TBL] [Abstract][Full Text] [Related]
9. Mechanisms of action of antiresorptive therapies of postmenopausal osteoporosis. Stepan JJ; Alenfeld F; Boivin G; Feyen JH; Lakatos P Endocr Regul; 2003 Dec; 37(4):225-38. PubMed ID: 15106819 [TBL] [Abstract][Full Text] [Related]
10. Ten years of alendronate treatment for osteoporosis in postmenopausal women. Bjarnason NH N Engl J Med; 2004 Jul; 351(2):190-2; author reply 190-2. PubMed ID: 15247362 [No Abstract] [Full Text] [Related]
11. [To increase bone density faster and stronger]. MMW Fortschr Med; 2005 May; 147(18):44-5. PubMed ID: 15934589 [No Abstract] [Full Text] [Related]
13. [Parathyroid and bone. Role of parathyroid hormone in the treatment of osteoporosis]. Nakamura T Clin Calcium; 2007 Dec; 17(12):1823-9. PubMed ID: 18057656 [TBL] [Abstract][Full Text] [Related]
14. Parathyroid hormone plus alendronate--a combination that does not add up. Khosla S N Engl J Med; 2003 Sep; 349(13):1277-9. PubMed ID: 14500803 [No Abstract] [Full Text] [Related]
16. Marked reduction of bone turnover by alendronate attenuates the acute response of bone resorption marker to endogenous parathyroid hormone. Zikan V; Stepan JJ Bone; 2009 Apr; 44(4):634-8. PubMed ID: 19150421 [TBL] [Abstract][Full Text] [Related]
17. Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. Arlot M; Meunier PJ; Boivin G; Haddock L; Tamayo J; Correa-Rotter R; Jasqui S; Donley DW; Dalsky GP; Martin JS; Eriksen EF J Bone Miner Res; 2005 Jul; 20(7):1244-53. PubMed ID: 15940379 [TBL] [Abstract][Full Text] [Related]
18. Monitoring alendronate therapy for osteoporosis. Braga de Castro Machado A; Hannon R; Eastell R J Bone Miner Res; 1999 Apr; 14(4):602-8. PubMed ID: 10234582 [TBL] [Abstract][Full Text] [Related]
19. Effects of alendronate on bone mass in patients with primary biliary cirrhosis and osteoporosis: preliminary results after one year. Musialik J; Petelenz M; Gonciarz Z Scand J Gastroenterol; 2005 Jul; 40(7):873-4. PubMed ID: 16109666 [No Abstract] [Full Text] [Related]
20. [Effects of the combined raloxifene-sodium fluoride therapy on bone mass and bone turnover in women with postmenopausal osteoporosis]. Celi M; Letizia C; Ragno A; Minisola S; D'Erasmo E; Mazzuoli GF Minerva Med; 2002 Dec; 93(6):471-8. PubMed ID: 12515970 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]